In the dynamic field of pharmaceutical research and development, specific chemical intermediates play indispensable roles, facilitating the creation of life-saving medications. 6-Hydroxy-3,4-dihydro-1H-quinolin-2-one (CAS 54197-66-9) is one such compound, recognized for its importance in the synthesis and study of various pharmaceuticals, most notably Cilostazol.

This heterocyclic compound, appearing typically as a white to tan powder or crystalline solid, is valued for its purity, often exceeding 95% (HPLC). With a molecular formula of C9H9NO2 and a molecular weight of 163.17, it is a well-characterized substance with a melting point range of 236-240°C. These attributes make it a reliable component for precision chemical synthesis in R&D settings.

The significance of 6-Hydroxy-3,4-dihydro-1H-quinolin-2-one is multifaceted. Primarily, it functions as a key intermediate in the synthesis of Cilostazol, a drug used to treat symptoms of intermittent claudication, thereby improving blood flow. Its presence as a metabolite of Cilostazol also makes it crucial for pharmacokinetic and pharmacodynamic studies, aiding researchers in understanding drug absorption, distribution, metabolism, and excretion (ADME) profiles. This dual role makes it a compound of interest for drug discovery, formulation development, and bioanalytical research.

For pharmaceutical companies and research institutions seeking to buy this vital compound, sourcing from a reputable manufacturer or supplier is essential. Many leading chemical providers, particularly those operating from China, offer this intermediate with a strong emphasis on quality control and competitive pricing. When inquiring about its availability, R&D professionals should look for suppliers who can guarantee high purity, provide comprehensive technical data, and offer efficient logistics. Exploring options for bulk purchases can lead to cost savings, making it easier to integrate this intermediate into ongoing projects.

By understanding the critical role and sourcing considerations for 6-Hydroxy-3,4-dihydro-1H-quinolin-2-one, pharmaceutical R&D teams can ensure the smooth progression of their drug development pipelines and contribute to advancements in healthcare.